The weekly litigation news digest is live. Subscribe now

IP Verse

Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy - EP3126390

The patent EP3126390 was granted to Cellectis on Oct 16, 2019. The application was filed on Apr 2, 2015 under application number EP15713513A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3126390

CELLECTIS
Application Number
EP15713513A
Filing Date
Apr 2, 2015
Status
Granted And Under Opposition
Sep 13, 2019
Publication Date
Oct 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJul 14, 2020WICHMANNADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2004058414
INTERNATIONAL-SEARCH-REPORTUS2013309223
INTERNATIONAL-SEARCH-REPORTWO2004043344
INTERNATIONAL-SEARCH-REPORTWO2011036183
INTERNATIONAL-SEARCH-REPORTWO2012079000
OPPOSITIONUS2012251554
OPPOSITIONWO2004043344
OPPOSITIONWO2013123061
OPPOSITIONWO2013173496
OPPOSITIONWO2013176915

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents